Research programme: cannabinoid based therapeutics - Therapix Biosciences

Drug Profile

Research programme: cannabinoid based therapeutics - Therapix Biosciences

Alternative Names: Dronabinol/palmitoylethanolamide combination therapies - Therapix Biosciences; Palmitoylethanolamide; Palmitoylethanolamide combination therapies - Therapix; THX 120; THX 130; THX 150; THX-160; THX-ULD01

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dekel Pharmaceuticals
  • Developer The Tel Aviv Sourasky Medical Center; Therapix Biosciences; Weizmann Institute of Science
  • Class Analgesics; Antibacterials; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Cognition disorders; Opioid abuse
  • Research Gilles de la Tourette's syndrome; Inflammation; Pain

Most Recent Events

  • 11 Jul 2018 Therapix Biosciences plans to license cannabinoid-based drug pipeline to Cure pharmaceuticals
  • 10 Nov 2017 Therapix Biosciences in-licenses synthetic cannabinoids for Opioid abuse from Yissum
  • 10 Nov 2017 Preclinical trials in Opioid abuse in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top